Post-operative Cataract Surgery Inflammation Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Mallinckrodt Pharma, Salix Pharma, GlaxoSmithKline, Pfizer Inc.

The Key Post-operative Cataract Surgery Inflammation Companies in the market include - Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical, Merck & Co., Inc., Oculis, Formosa Pharmaceuticals, AimMaxTherapeutics, Salvat Laboratories, Azidus Brasil, Bausch & Lomb Incorporated, Laboratorios Poen, Oculis, Alcon Research, and others.

DelveInsight's "Post-operative Cataract Surgery Inflammation Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Post-operative Cataract Surgery Inflammation, historical and forecasted epidemiology as well as the Post-operative Cataract Surgery Inflammation market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Post-operative Cataract Surgery Inflammation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post-operative Cataract Surgery Inflammation Market Forecast [https://www.delveinsight.com/sample-request/post-operative-cataract-surgery-inflammation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Post-operative Cataract Surgery Inflammation Market Report:

*
The Post-operative Cataract Surgery Inflammation market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In December 2024, VivaVision Biotech, a clinical-stage, privately owned biotechnology company dedicated to developing therapies for ocular diseases, today revealed positive topline results from its U.S. Phase 2 clinical trial of VVN461-CS-201. This potent non-steroidal dual JAK1/TYK2 immunomodulator is being developed to treat post-operative inflammation following cataract surgery.

*
In December 2024, VivaVision Biotech, based in China, plans to move forward with its non-steroidal therapy, VVN461-CS-201 (VVN461), into a Phase III trial after the candidate successfully met the primary endpoint in a Phase II U.S. study focused on treating post-operative inflammation following cataract surgery.

*
There are around 10 million cataract procedures conducted each year to treat the estimated 95 million people who have them worldwide. As a result, cataract surgery is among the most frequently carried out medical treatments worldwide. After cataract surgery, postoperative inflammation is a typical consequence

*
According to the American Academy of Ophthalmology (2023), more than 24.4 million Americans aged 40 and older have cataracts. About half of all Americans have cataracts by the age of 75

*
The National Eye Institute (2020) reports that the US had a 17.11% prevalence of cataracts in 2010. More over half of all Americans 80 years of age and older either have cataracts or have undergone cataract surgery

*
Key Post-operative Cataract Surgery Inflammation Companies: Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Oculis, Formosa Pharmaceuticals, AimMaxTherapeutics, Salvat Laboratories, Azidus Brasil, Bausch & Lomb Incorporated, Laboratorios Poen, Oculis, Alcon Research, and others

*
Key Post-operative Cataract Surgery Inflammation Therapies: OCS-01, APP13007, SVT15473, Ster, Bromfenac, Difluprednate, OCS-01 - Dexamethasone, Nepafenac Ophthalmic Suspension, and others

*
The Post-operative Cataract Surgery Inflammation epidemiology based on gender analyzed that females were more affected by cataract than men

*
The Post-operative Cataract Surgery Inflammation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post-operative Cataract Surgery Inflammation pipeline products will significantly revolutionize the Post-operative Cataract Surgery Inflammation market dynamics.

Post-operative Cataract Surgery Inflammation Overview

A cataract is a clouded spot in the eye's lens, which is clear and helps to concentrate light. Cataracts are quite frequent in older people. In actuality, more than half of all Americans 80 years of age and older either have cataracts or have undergone cataract surgery. Additionally, it is the leading global cause of blindness.

Get a Free sample for the Post-operative Cataract Surgery Inflammation Market Report

https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-market [https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Post-operative Cataract Surgery Inflammation Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Post-operative Cataract Surgery Inflammation Epidemiology Segmentation:

The Post-operative Cataract Surgery Inflammation market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Post-operative Cataract Surgery Inflammation

*
Prevalent Cases of Post-operative Cataract Surgery Inflammation by severity

*
Gender-specific Prevalence of Post-operative Cataract Surgery Inflammation

*
Diagnosed Cases of Episodic and Chronic Post-operative Cataract Surgery Inflammation

Download the report to understand which factors are driving Post-operative Cataract Surgery Inflammation epidemiology trends @ Post-operative Cataract Surgery Inflammation Epidemiology Forecast [https://www.delveinsight.com/sample-request/post-operative-cataract-surgery-inflammation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Post-operative Cataract Surgery Inflammation Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-operative Cataract Surgery Inflammation market or expected to get launched during the study period. The analysis covers Post-operative Cataract Surgery Inflammation market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Post-operative Cataract Surgery Inflammation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post-operative Cataract Surgery Inflammation Therapies and Key Companies

*
OCS-01: Oculis

*
APP13007: Formosa Pharmaceuticals/AimMaxTherapeutics

*
SVT15473: Salvat Laboratories

*
Ster: Azidus Brasil

*
Bromfenac: Bausch & Lomb Incorporated

*
Difluprednate: Laboratorios Poen

*
OCS-01 - Dexamethasone: Oculis

*
Nepafenac Ophthalmic Suspension: Alcon Research

Discover more about therapies set to grab major Post-operative Cataract Surgery Inflammation market share @ Post-operative Cataract Surgery Inflammation Treatment Market [https://www.delveinsight.com/sample-request/post-operative-cataract-surgery-inflammation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Post-operative Cataract Surgery Inflammation Market Strengths

*
Advances in surgical techniques

*
Advances in the understanding of ophthalmology

*
Pipeline consists of late and early stage candidates.

Post-operative Cataract Surgery Inflammation Market Opportunities

*
Uptake of potential emerging therapies with better clinical profile expected to be medium-fast due to the present unmet needs

*
The side effects associated with therapies currently give a window of opportunity to pharma payer to bring in novel therapies.

Scope of the Post-operative Cataract Surgery Inflammation Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Post-operative Cataract Surgery Inflammation Companies: Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Oculis, Formosa Pharmaceuticals, AimMaxTherapeutics, Salvat Laboratories, Azidus Brasil, Bausch & Lomb Incorporated, Laboratorios Poen, Oculis, Alcon Research, and others

*
Key Post-operative Cataract Surgery Inflammation Therapies: OCS-01, APP13007, SVT15473, Ster, Bromfenac, Difluprednate, OCS-01 - Dexamethasone, Nepafenac Ophthalmic Suspension, and others

*
Post-operative Cataract Surgery Inflammation Therapeutic Assessment: Post-operative Cataract Surgery Inflammation current marketed and Post-operative Cataract Surgery Inflammation emerging therapies

*
Post-operative Cataract Surgery Inflammation Market Dynamics: Post-operative Cataract Surgery Inflammation market drivers and Post-operative Cataract Surgery Inflammation market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Post-operative Cataract Surgery Inflammation Unmet Needs, KOL's views, Analyst's views, Post-operative Cataract Surgery Inflammation Market Access and Reimbursement

To know more about Post-operative Cataract Surgery Inflammation companies working in the treatment market, visit @ Post-operative Cataract Surgery Inflammation Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/post-operative-cataract-surgery-inflammation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Post-operative Cataract Surgery Inflammation Market Report Introduction

2. Executive Summary for Post-operative Cataract Surgery Inflammation

3. SWOT analysis of Post-operative Cataract Surgery Inflammation

4. Post-operative Cataract Surgery Inflammation Patient Share (%) Overview at a Glance

5. Post-operative Cataract Surgery Inflammation Market Overview at a Glance

6. Post-operative Cataract Surgery Inflammation Disease Background and Overview

7. Post-operative Cataract Surgery Inflammation Epidemiology and Patient Population

8. Country-Specific Patient Population of Post-operative Cataract Surgery Inflammation

9. Post-operative Cataract Surgery Inflammation Current Treatment and Medical Practices

10. Post-operative Cataract Surgery Inflammation Unmet Needs

11. Post-operative Cataract Surgery Inflammation Emerging Therapies

12. Post-operative Cataract Surgery Inflammation Market Outlook

13. Country-Wise Post-operative Cataract Surgery Inflammation Market Analysis (2019-2032)

14. Post-operative Cataract Surgery Inflammation Market Access and Reimbursement of Therapies

15. Post-operative Cataract Surgery Inflammation Market Drivers

16. Post-operative Cataract Surgery Inflammation Market Barriers

17. Post-operative Cataract Surgery Inflammation Appendix

18. Post-operative Cataract Surgery Inflammation Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=postoperative-cataract-surgery-inflammation-market-growth-to-accelerate-in-forecast-period-20232032-delveinsight-analyzes-mallinckrodt-pharma-salix-pharma-glaxosmithkline-pfizer-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.